Document Detail

Effects of oral paricalcitol on hyperparathyroidism and proteinuria in peritoneal dialysis patients.
MedLine Citation:
PMID:  22073844     Owner:  NLM     Status:  In-Process    
Severe secondary hyperparathyroidism is a complication of chronic kidney disease. Paricalcitol is a vitamin D receptor activator with efficacy in the treatment of hyperparathyroidism that also has the minor side effects of hypercalcemia and hyperphosphatemia. As a pleiotropic effect, paricalcitol reduces proteinuria in patients with chronic kidney disease stages 2-4. Oral paricalcitol offers an alternative way to treat hyperparathyroidism and proteinuria in peritoneal dialysis patients. Our prospective study enrolled 18 patients with hyperparathyroidism (6 with diabetes also) who were given oral paricalcitol at initial dose of 1-2 microg daily, depending on their level of intact parathyroid hormone (iPTH). In the 1st month, iPTH levels declinedsignificantly to 295 +/- 147 pg/mL from 670 +/- 318 pg/mL, and by the 3rd month, they declined to 192 +/- 340 pg/mL (p < 0.001). Without modifications to doses of angiotensin converting-enzyme inhibitor or angiotensin II receptor blocker, proteinuria declined in the 1st month to 1.41 +/- 1.5 g/L from 1.68 +/- 1.7 (p = 0.006) and, in the 3rd month, without statistical significance. In some patients, the dose of paricalcitol was reduced because of iPTH levels that were too low at 1 month. The patients whose doses of paricalcitol were maintained at 3 months showed a reduction in proteinuria to 2.1 +/- 2.1 g/L daily from 3.1 +/- 2. 7 g/L (p = 0.04) and to 2.3 +/- 2.1 g/day from 5.0 +/- 6.1 g/day (p = 0.012). In conclusion, paricalcitol is effective for treating hyperparathyroidism in patients on peritoneal dialysis and seems also to have an antiproteinuric effect in these patients.
Francisco Coronel; Beatriz Rodríguez-Cubillo; Secundin Cigarrán; Antonio Gomis
Related Documents :
1347654 - Drug treatment of copd. controversies about agents and how to deliver them.
9793374 - Challenging questions in treating bronchitis.
22259654 - Idiopathic chronic urticaria and thyroid autoimmunity: experience of a single center.
16412624 - Prevalence of nutritional depletion in a large out-patient population of patients with ...
7510724 - Lymph node hyalinisation in rheumatoid arthritis and systemic sclerosis.
1789694 - Hypertension in the elderly is associated with white matter lesions and cognitive decline.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Advances in peritoneal dialysis. Conference on Peritoneal Dialysis     Volume:  27     ISSN:  1197-8554     ISO Abbreviation:  Adv Perit Dial     Publication Date:  2011  
Date Detail:
Created Date:  2011-11-11     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9104803     Medline TA:  Adv Perit Dial     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  130-3     Citation Subset:  IM    
Nephrology Department, Hospital Clínico San Carlos, Madrid, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Subacute polyneuropathy in a patient undergoing peritoneal dialysis: clinical features and new patho...
Next Document:  Does cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism, ...